Introduction. Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease nowadays which has contributed to significant cardiovascular and hepatic morbidity and mortality. Recognizing the metabolic concept resulted in an evolution in disease nomenclature, as well as the development of innovative treatments for MASLD, the hepatic manifestation of metabolic syndrome.

Objective. To present contemporary trends in the management of MASLD.

Methods. For the search methodology, we used the PubMed database. We employed the following keywords to search for original articles,  reviews, and clinical guidelines from 2018. to 2025. year, such as „NAFLD/MASLD“, „NAFLD/MASLD biomarkers“, „NAFLD/MASLD diagnostic scores“, „NAFLD/MASLD innovative therapy“. We used original articles and reviews written in English, Serbian and Balkan-familiar languages. Special attention was given to the FIB-4 algorithm, newly developed non-invasive scores (SAFE, LiverRisk, MAFS), and biomarkers (MDA, 8-OHdG, CK-18, PRO-C3).

Results. MASLD has been associated to an increased risk of liver fibrosis and cirrhosis, hepatocellular carcinoma (HCC), and cardiovascular diseases. Emerging biomarkers enable early and accurate diagnosis and monitoring of treatment response, while innovative treatments including PPAR agonists, GLP-1 receptor agonists, and Resmetirom are mapping the personalized MASLD treatment.

Conclusion. MASLD is a chronic systemic disease requiring a multidisciplinary approach. Proper diagnosis and personalized innovative therapy create the favorable conditions for reducing cardiovascular and hepatic morbidity and mortality.

Stafilokokni toksični šok sindrom (STŠS) se obično javlja kod novorođenčadi i dece, ali se povremeno može javiti i kod odraslih. U tom slučaju, obično ukazuje na disfunkciju imunog sistema. Prikazan je slučaj kritično-obolelog odraslog muškarca sa STŠS i simptomima i znacima životno-ugrožavajuće sistemske infekcije (hemodinamska nestabilnost, akutna insuficijencija bubrega, konfuzija). Nakon završenog lečenja (anti-stafilokoni antibiotici, hemodijaliza, vazopresori, suportivna i simptomatska terapija), postignuta je potpuna remisija kod obolelog. Pravovremena dijagnostika i adekvatan tretman je glavno uporište u lečenju STŠS kod odraslih.